Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01284478 · ClinicalTrials.gov registry record · Phase 2
Ozurdex for Combined Pseudophakic Cystoid Macular Edema and Diabetic Macular Edema After Cataract Surgery
A Phase 2 study, sponsored by Northern California Retina Vitreous Associates.
- Completed
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT01284478 is a Phase 2 study that has completed, run by Northern California Retina Vitreous Associates. The registered enrollment target is 6 participants.
The verdict
NCT01284478, a Phase 2 study, has completed, sponsored by Northern California Retina Vitreous Associates.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of the study is to determine where a sustained steroid delivery system (Ozurdex,Allergan) is safe and effective to treat Cystoid Macular Edema in diabetic patients after Cataract Surgery
Interventions
- DRUG Dexamethasone Implant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2011-01 |
| Est. Completion | 2012-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01284478
The ClinicalTrials.gov registry entry for NCT01284478 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northern California Retina Vitreous Associates, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Dexamethasone Implant is the first listed.
NCT01284478 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01284478 about?
NCT01284478 is a clinical study titled "Ozurdex for Combined Pseudophakic Cystoid Macular Edema and Diabetic Macular Edema After Cataract Surgery". The purpose of the study is to determine where a sustained steroid delivery system (Ozurdex,Allergan) is safe and effective to treat Cystoid Macular Edema in diabetic patients after Cataract Surgery
What is the current status of trial NCT01284478?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2011-01. Estimated completion is 2012-10.
What interventions are being tested in trial NCT01284478?
The interventions under investigation include: Dexamethasone Implant (DRUG).
Who is sponsoring clinical trial NCT01284478?
This trial is sponsored by Northern California Retina Vitreous Associates, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.